TY  - JOUR
AU  - Bellmunt, Joaquim
AU  - Valderrama, Begoña P
AU  - Puente, Javier
AU  - Grande, Enrique
AU  - Bolós, M Victoria
AU  - Lainez, Nuria
AU  - Vázquez, Sergio
AU  - Maroto, Pablo
AU  - Climent, Miguel Ángel
AU  - Garcia Del Muro, Xavier
AU  - Arranz, José Ángel
AU  - Durán, Ignacio
PY  - 2022
DO  - 10.1016/j.critrevonc.2022.103683
UR  - http://hdl.handle.net/10668/22144
T2  - Critical reviews in oncology/hematology
AB  - Management of first-line advanced urothelial carcinoma (UC) has consisted during the past three decades in the administration of platinum-based chemotherapy followed by observation. Despite moderate to high response rates to first-line treatment, most...
LA  - en
KW  - Antibody drug-conjugate (ADC)
KW  - Avelumab
KW  - Bladder cancer
KW  - Checkpoint inhibitors (CPIs)
KW  - Platinum-based chemotherapy
KW  - Switch maintenance
KW  - Urothelial carcinoma (UC)
KW  - Carcinoma, Transitional Cell
KW  - Disease Management
KW  - Humans
KW  - Immunotherapy
KW  - Neoplasm Recurrence, Local
KW  - Urinary Bladder Neoplasms
TI  - Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management.
TY  - research article
VL  - 174
ER  -